Antibodies against the S100P protein for the treatment and diagnosis of cancer

A method of treatment of cancer that expresses S100P protein, the method comprising administering to a subject in need of said treatment a pharmaceutically effective amount of a compound selected from the group consisting of:

• (i) an antibody that binds specifically to the S100P protein of SEQ ID No. 1 or of a fragment thereof with capacity for binding to the antigen;
• and
• (ii) a conjugate comprising a specific anti-S100P monoclonal antibody produced by a hybridoma selected from the group consisting of ECACC 10121601, ECACC 10121602, ECACC 10121603 and ECACC 10121604;
• or a polypeptide having at least one fragment of the sequence of said monoclonal antibody with capacity for binding to S100P protein of SEQ ID No. 1, said fragment including the sequence of the 6 CDRs of said monoclonal antibody and a second component selected from the group consisting of:
• (a) a cytotoxic agent;
• (b) an antiangiogenic agent;
• and
• (c) an antimetastatic agent.